The treatment of PDAC PDTX models with MEK and CDK4/6 inhibitors was demonstrated to have a profound impact on the myeloid and T-cell populations within the tumor compartment, eliciting sensitivity to anti-PD1 (programmed cell death protein 1) therapy in immune-competent models [119]. Here, MAP2K7 is linked to neoplasm.